API COMMERCIAL SUPPLY AGREEMENT by and between AMARIN PHARMACEUTICALS IRELAND LTD. and CHEMPORT INC. Dated as of May 25, 2011Api Commercial Supply Agreement • March 1st, 2022 • Amarin Corp Plc\uk • Pharmaceutical preparations • New York
THIS API COMMERCIAL SUPPLY AGREEMENT (this “Agreement”) is entered into and dated as of the 25th day of May, 2011 (the “Effective Date”) by and between Amarin Pharmaceuticals Ireland Ltd., a corporation organized under the laws of Ireland and having its principal office at First Floor, Block 3, The Oval, Shelbourne Road, Ballsbridge, Dublin 4, Ireland (“Amarin”), and Chemport Inc., a corporation organized under the laws of South Korea and having its principal offices at 15-1, Dongsu-dong, Naju-si, Jeollanam-do 520-330 Korea (“Chemport”). Amarin and Chemport are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
AMENDMENT TO API COMMERCIAL SUPPLY AGREEMENTApi Commercial Supply Agreement • March 1st, 2022 • Amarin Corp Plc\uk • Pharmaceutical preparations
This AMENDMENT TO API COMMERCIAL SUPPLY AGREEMENT (the “Amendment”) is made as of this 4 day of April, 2012 (the “Amendment Effective Date”), by and between Amarin Pharmaceuticals Ireland Ltd., a corporation organized under the laws of Ireland and having its principal office at First Floor, Block 3, The Oval, Shelbourne Road, Ballsbridge, Dublin 4, Ireland (“Amarin”), and Chemport Inc., a corporation organized under the laws of South Korea and having its principal offices at 15-1, Dongsu-dong, Naju-si, Jeollanam-do 520-330 Korea (“Chemport”).
SECOND AMENDMENT TO API COMMERCIAL SUPPLY AGREEMENTApi Commercial Supply Agreement • November 8th, 2012 • Amarin Corp Plc\uk • Pharmaceutical preparations
This SECOND AMENDMENT TO API COMMERCIAL SUPPLY AGREEMENT (the “Amendment”) is made as of this 19th day of July, 2012 (the “Amendment Effective Date”), by and between Amarin Pharmaceuticals Ireland Ltd., a corporation organized under the laws of Ireland and having its principal office at 2 Pembroke House, Upper Pembroke Street, #28-32, Dublin 2, Ireland (“Amarin”), and Chemport Inc., a corporation organized under the laws of South Korea and having its principal offices at 15-1, Dongsu-dong, Naju-si, Jeollanam-do 520-330 Korea (“Chemport”).
AMENDMENT TO API COMMERCIAL SUPPLY AGREEMENTApi Commercial Supply Agreement • August 8th, 2012 • Amarin Corp Plc\uk • Pharmaceutical preparations
This AMENDMENT TO API COMMERCIAL SUPPLY AGREEMENT (the “Amendment”) is made as of this 4 day of April, 2012 (the “Amendment Effective Date”), by and between Amarin Pharmaceuticals Ireland Ltd., a corporation organized under the laws of Ireland and having its principal office at First Floor, Block 3, The Oval, Shelbourne Road, Ballsbridge, Dublin 4, Ireland (“Amarin”), and Chemport Inc., a corporation organized under the laws of South Korea and having its principal offices at 15-1, Dongsu-dong, Naju-si, Jeollanam-do 520-330 Korea (“Chemport”).
SECOND AMENDMENT TO API COMMERCIAL SUPPLY AGREEMENTApi Commercial Supply Agreement • March 1st, 2022 • Amarin Corp Plc\uk • Pharmaceutical preparations
This SECOND AMENDMENT TO API COMMERCIAL SUPPLY AGREEMENT (the “Amendment”) is made as of this 19th day of July, 2012 (the “Amendment Effective Date”), by and between Amarin Pharmaceuticals Ireland Ltd., a corporation organized under the laws of Ireland and having its principal office at 2 Pembroke House, Upper Pembroke Street, #28-32, Dublin 2, Ireland (“Amarin”), and Chemport Inc., a corporation organized under the laws of South Korea and having its principal offices at 15-1, Dongsu-dong, Naju-si, Jeollanam-do 520-330 Korea (“Chemport”).
API COMMERCIAL SUPPLY AGREEMENTApi Commercial Supply Agreement • November 8th, 2021 • Cara Therapeutics, Inc. • Pharmaceutical preparations
THIS API COMMERCIAL SUPPLY AGREEMENT (this “Agreement”) is entered into and effective as of July, 5th, 2021 (the “Effective Date”) by and between POLYPEPTIDE LABORATORIES S.A., a limited liability corporation organized under the laws of France and having its principal office at 7, rue de Boulogne, 67100 Strasbourg, France (“PolyPeptide”), and CARA THERAPEUTICS, a limited liability company having its principal offices at 4 Stamford Plaza, 107 Elm Street, 9th Floor, Stamford, CT, 06902 USA (“CARA”).
API COMMERCIAL SUPPLY AGREEMENT (DENUFOSOL) by and between INSPIRE PHARMACEUTICALS, INC. and FINORGA S.A.S. Dated as of December 14, 2010Api Commercial Supply Agreement • December 22nd, 2010 • Inspire Pharmaceuticals Inc • Pharmaceutical preparations • New York
THIS API COMMERCIAL SUPPLY AGREEMENT (DENUFOSOL) (this “Agreement”) is entered into and dated as of the 14th day of December, 2010 (the “Effective Date”) by and between Inspire Pharmaceuticals, Inc., a Delaware corporation having its principal office at 4222 Emperor Boulevard, Suite 200, Durham, North Carolina 27703-8466, U.S.A. (“Inspire”) and Finorga S.A.S., a corporation organized and existing under the laws of France, having a place of business at Route de Givors, 38670 Chasse sur Rhône, France (“Novasep”). Inspire and Novasep are sometimes referred to herein individually as a “Party” and collectively as “Parties.”
